Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6419
    -0.0006 (-0.10%)
     
  • OIL

    83.14
    +0.41 (+0.50%)
     
  • GOLD

    2,400.00
    +2.00 (+0.08%)
     
  • Bitcoin AUD

    100,730.61
    +4,661.84 (+4.85%)
     
  • CMC Crypto 200

    1,332.52
    +19.90 (+1.52%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0891
    +0.0017 (+0.15%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,818.39
    -58.66 (-0.74%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,661.08
    -176.32 (-0.99%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Is Novavax Stock a Buy Now?

Is Novavax Stock a Buy Now?

Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.